Kairos Pharma, LTD. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Filing dated 2026-09-14 contains Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits) but the actual text content is not provided in this submission extract—only document metadata, file listings (37 documents including 25 graphics), and XBRL data files are shown. No counterparties, dollar amounts, dates, share counts, or concrete business events can be identified from the information available.
Why this rating
Cannot assess substance; filing structure suggests disclosure event, but text absent. For $6.9M company, without concrete data, default to routine administrative filing.
Extracted items
- 7.01 Reg FD disclosure
- 9.01 exhibits
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.